1-3 of 3
Luciano J. Costa
Close
Sort by
Journal Articles

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma

Clinical Trials & Observations
Luciano J. Costa, Faith E. Davies, Gregory P. Monohan, Tibor Kovacsovics, Nicholas Burwick, Andrzej Jakubowiak, Jonathan L. Kaufman, Wan-Jen Hong, Monique Dail, Ahmed Hamed Salem, Xiaoqing Yang, Abdullah A. Masud, Wijith Munasinghe, Jeremy A. Ross, Orlando F. Bueno, Shaji K. Kumar, Edward A. Stadtmauer
Journal: Blood Advances
Blood Adv (2021) 5 (19): 3748–3759.
https://doi.org/10.1182/bloodadvances.2020004146
Published: 2021
Includes: Supplemental data
Journal Articles

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN

Clinical Trials & Observations
Peter M. Voorhees, Cesar Rodriguez, Brandi Reeves, Nitya Nathwani, Luciano J. Costa, Yana Lutska, Padma Bobba, Daniela Hoehn, Huiling Pei, Jon Ukropec, Ming Qi, Thomas S. Lin, Paul G. Richardson
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1092–1096.
https://doi.org/10.1182/bloodadvances.2020003642
Published: 2021
Journal Articles

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States

Clinical Trials & Observations
Luciano J. Costa, Ilene K. Brill, James Omel, Kelly Godby, Shaji K. Kumar, Elizabeth E. Brown
Journal: Blood Advances
Blood Adv (2017) 1 (4): 282–287.
https://doi.org/10.1182/bloodadvances.2016002493
Published: 2017
Includes: Supplemental data